Vol. 4, Issue 1, Part A (2024)

Aims: The aim of this study was; statistical analysis of the clinico-epidemiological characteristics and different prognostic factors affecting the treatment outcome in the patients with NSCLC/SCLC and assessments the response and the adverse events of treatment. 
Patients and Methods: This is a retrospective clinic-epidemiological study was carried out to evaluate the patients presented with NSCLC and SCLC and treated at Clinical Oncology Department Tanta University hospital during a period between January 2015 to December 2019 with a minimum follow up period of 6 months. 
Results: The SCLC was represented in 14.4% of patients, while NSCLC was represented in 85.6%. Most of the patients were presented with stage IV (49.5%) while only (1.2%) of the patients were presented with stage I. lung cancer represented the 4th most common type of cancer in our department. Adenocarcinoma was prevelant among the non-smoker and smoker patients (53.4% and 45% respectively). (5.3%) of patients with SCLC had achieved CR while only (1.35%) of patients with NSCLC had achieved CR. At the end of this study, there were 48 patients (9.2%) alive and 473 patients (90.8%) dead. 
Conclusion: In the realm of lung cancer prevention, the pivotal preventive strategy lies in the regulation of tobacco smoking. The prognosis for lung cancer sufferers tends to be unfavorable due to delayed detection and the limited scope for surgical intervention. The establishment of multidisciplinary cohorts is imperative for the purpose of deliberating on optimal therapeutic approaches for individual patients.